

European Journal of Nuclear Medicine and Molecular Imaging

Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease

--Manuscript Draft--

| | | |
|--|---|---------------------|
| Manuscript Number: | EJNM-D-19-00703R1 | |
| Full Title: | Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease | |
| Article Type: | Review Article | |
| Corresponding Author: | Delphine Boche, PhD University of Southampton Southampton, Hampshire UNITED KINGDOM | |
| Corresponding Author Secondary Information: | | |
| Corresponding Author's Institution: | University of Southampton | |
| Corresponding Author's Secondary Institution: | | |
| First Author: | Delphine Boche, PhD | |
| First Author Secondary Information: | | |
| Order of Authors: | Delphine Boche, PhD Alexander Gerhard Elena Rodriguez-Vieitez | |
| Order of Authors Secondary Information: | | |
| Funding Information: | Alzheimer's Research UK | Prof Delphine Boche |
| Abstract: | <p>Neuroinflammation, as defined by the activation of microglia and astrocytes, has emerged in the last years as a key element of the pathogenesis of neurodegenerative diseases based on genetic findings and preclinical and human studies. This has raised the need for new methodologies to assess and follow glial activation in patients, prompting the development of PET ligands for molecular imaging of glial cells and novel structural MRI and DTI tools leading to a multimodal approach.</p> <p>The present review describes the recent advancements in microglia and astrocyte biology in the context of health, ageing and Alzheimer's disease, the most common dementia worldwide. The review further delves in molecular imaging discussing the challenges associated with past and present targets, including conflicting findings, and finally presenting novel methodologies currently explored to improve our in vivo knowledge of the neuroinflammatory patterns in Alzheimer's disease. With glial cell activation as a potential therapeutic target in neurodegenerative diseases, the translational research between cell biologists, chemists, physicists, radiologists and neurologists should be strengthened.</p> | |
| Response to Reviewers: | 12 July 2019 Dear Prof Chiti, Revision of the manuscript entitled: "Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease" – EJNM-D-19-00703 As requested, we have modified the text in the following sections (track changes in the manuscript): - 'Molecular imaging targets for microglia in Alzheimer's disease and mild cognitive impairment (MCI) patients'; sub-section 'PET studies using TSPO tracers' (paragraph 7-10), pages 5-8. - 'PET studies using non-TSPO tracers for neuroinflammatory changes in AD' | |

(paragraph 2), page 8.
- section 'Astrocytes in Alzheimer's disease' (paragraph 1), page 9.
- section 'Molecular imaging targets for astrocytes'; sub-section 'metabolic markers' (paragraph 2), page 11.

A statement on Ethical approval for the figure 4 has been added on page 13.

We hope that the paper is now acceptable for submission.

Thank you for your consideration in advance.

Yours sincerely

Delphine Boche

Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease

Delphine Boche¹, Alexander Gerhard^{2,3}, Elena Rodriguez-Vieitez⁴
on behalf of the MINC Faculty

¹Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

²Department of Nuclear Medicine and Geriatric Medicine, University Hospital Essen, Essen, Germany

³Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United-Kingdom

⁴Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden

ORCID iD

Delphine Boche: <https://orcid.org/0000-0002-5884-130X>

Alexander Gerhard: <https://orcid.org/0000-0002-8071-6062>

Elena Rodriguez-Vieitez: <https://orcid.org/0000-0002-6639-8141>

Corresponding Author

Prof. Delphine Boche, Clinical Neurosciences, Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Mailpoint 806, Southampton SO16 6YD, United Kingdom.

Phone: +44 (0) 2381 206 085

Email: d.boche@soton.ac.uk

Abstract

Neuroinflammation, as defined by the activation of microglia and astrocytes, has emerged in the last years as a key element of the pathogenesis of neurodegenerative diseases based on genetic findings and preclinical and human studies. This has raised the need for new methodologies to assess and follow glial activation in patients, prompting the development of PET ligands for molecular imaging of glial cells and novel structural MRI and DTI tools leading to a multimodal approach.

The present review describes the recent advancements in microglia and astrocyte biology in the context of health, ageing and Alzheimer's disease, the most common dementia worldwide. The review further delves in molecular imaging discussing the challenges associated with past and present targets, including conflicting findings, and finally presenting novel methodologies currently explored to improve our *in vivo* knowledge of the neuroinflammatory patterns in Alzheimer's disease. With glial cell activation as a potential therapeutic target in neurodegenerative diseases, the translational research between cell biologists, chemists, physicists, radiologists and neurologists should be strengthened.

Keywords

TSPO, microglia, astrocyte, Alzheimer's disease, PET, MRI

Introduction

There is increasing evidence that inflammation plays a key role in the development and progression of neurodegenerative diseases such as Alzheimer's disease (AD), likely being involved in its etiology and as a disease-promoting factor [1, 2]. Indeed accumulating experimental, genetic and epidemiological data implicate the innate immune system in AD, most prominently involving genes for immune receptors or immune-related functions such as *APOE* (apolipoprotein E), *CRI* (complement receptor 1), *BINI* (bridging integrator 1), *CD33*, *TREM2* (triggering receptor expressed on myeloid cells 2) and *PICALM* (phosphatidylinositol binding clathrin assembly protein). These new developments have raised the interest in investigating glial cells towards understanding the origin of AD and to design novel disease-modifying therapies.

Neuropathologically, AD is defined by the aggregation and deposition of amyloid- β (A β) plaques in the parenchyma and hyperphosphorylated tau in neurons, and therefore AD has been mostly conceptualized as a proteinopathy. The majority of clinical trials have aimed at clearance of these protein forms, however with very limited success clinically [3]. While longitudinal neuroimaging studies using PET (positron-emission tomography) tracers for A β and tau suggest that A β precedes tau pathology [4], the mechanistic link between these two pathological features is not well known. Interestingly, new preclinical data suggests that neuroinflammation might be a possible link between A β and tau proteinopathies. In particular, A β aggregation may trigger activation of microglia and astrocytes, the cells of the brain immune system, leading to the release of neuroinflammatory markers that might be contributing to tau pathology and spreading [5, 6]. These studies have shown that microglia activation can lead to astrocyte activation and *vice-versa*, but the regional and temporal patterns of astrogliosis and microgliosis in relation to other pathophysiological changes are not well known. These recent findings stimulate further research on neuroimaging of microglia and astrocytes using PET tracers in combination with other imaging modalities and fluid biomarkers.

Microglia in the healthy brain

Microglia migrate from the yolk sac [7] and colonise the brain early during embryogenesis to form the resident immune cells of the brain. Their maintenance and expansion in the central nervous system (CNS) relies exclusively on their capacity of self-renewal without any further colonization [8-10]. The population remains stable over the lifetime with a slow turn-over [10], of an approximate lifespan of 4 years in humans [11], and they are the main identified proliferating cells in the human brain from the age of 3 years old [12]. Microglia are defined by a unique molecular signature, known as their *homeostatic signature*, which is driven by the expression of the transforming growth factor (TGF)- β 1 cytokine, differentiating them from the other brain cells and myeloid populations [13]. This signature encompasses expression of a specific set of genes reported in Table 1.

In humans, microglia represent 0.5 to 16% of the total brain cells [14], with significantly more cells in the white than in grey matter. They have a ramified morphology having multiple fine processes (Figure 1A-D), and time-lapse imaging experiments in mice have demonstrated that microglia are extremely motile cells, screening constantly the parenchyma via their processes [15]. During brain development, microglia participate in the wiring and maturation of the brain [16] by pruning excessive synapses [17] and influencing neurogenesis [18]. In adult, microglia survey and sense any changes in order to respond rapidly to any insult or injury [15], and participate in synaptic communication [19, 20]. The properties of sensing and interacting with their micro-environment are performed via microglia-specific transcripts termed the *microglial sensome* [21] with several of the

sensome genes identified later as components of the homeostatic signature such as *P2Y₁₂* [21, 13]. It is assumed that similar functions are performed by microglia in humans.

Ageing *per se* predisposes to peripheral inflammation, a concept known as “inflammaging” [22], and this concept is supported by the presence of altered mRNA expression and proteins of inflammation related-genes in the middle-aged human and mouse brain [23] (Table 1). In aged mice, the expression of the sensome genes are diminished [21]. Interestingly, the major changes of the expression profiles of immune and inflammation-related genes occur during the course of cognitively normal ageing rather than disease conditions and involve upregulation of genes coding for inflammasome signalling, Fcγ receptors and HLA [24]. Morphological microglial changes characterised by reduced branching and arborized area have been described in humans [25] (Figure 1E-G) suggesting that microglia become dysfunctional or senescent with ageing. These molecular and morphological changes imply that with age, microglia lose their neuroprotective properties associated with chronic neurodegeneration [26]. A recent study investigating the phenotype of aged human microglia highlighted that microglial ageing manifests as loss of function as well as gain of function changes to give a unique aged-related microglia phenotype [27]. This profile was enriched in susceptibility genes for AD but interestingly, independent from APOE4 the main risk factor for AD.

A number of concepts related to the phenotypes that microglia can acquire have emerged from experimental models. Microglial priming is defined as a prolonged and exaggerated immune challenge resulting from an acute inflammatory event in an ongoing inflammatory environment [28]; whereas innate immune memory is associated to cell reprogramming following a primary immune stimulus that leads to increased (trained) or decreased (tolerant) responses to a secondary inflammatory stimulus [29]. Primed or reprogrammed microglia have an enhanced response to a second stimulus. Therefore, an integrated nomenclature under the term of microglial memory was recently proposed to encompass both phenotypes [29] (Table 2). These concepts are important and highly relevant to the lifetime of infections in humans and to the microglial lifespan with some of cells reported to be more than 20 years old [11], and thus capable of remembering the inflammatory events [30, 31]. Indeed, even in the absence of brain injury, insult or infection, it is now acknowledged that systemic immunity will affect the brain immunity [32]. However, the relevance of the rodent experiments to humans is still unclear. To summarise, microglia are adaptive cells with the phenotype and morphology determined by their local environment (Table 1).

Microglia in Alzheimer’s disease

Genome wide association studies have highlighted variation in genes of the innate immunity as risk factors for AD, emphasizing the role of microglia, not only in responding to the neurodegeneration, but also in the onset and progression of the disease. Two microglial phenotypes have been determined from mouse AD models. The *Disease-Associated Microglia* (DAM) is characterised by low expression of homeostatic markers (e.g. *CX3CR1*, *P2y12*, *Tgfb1*) and elevated levels of lipid metabolism, phagocytosis, apoptosis and AD-associated genes (e.g. *APOE*, *Trem2*) [33]. Similarly, the *Microglial Neurodegenerative Phenotype* (MGnD) is driven by a rise APOE and apoptotic markers (e.g. *Axl*, *Clec7a*), and the fading of the microglial homeostatic signature [34] (Table 1). Both profiles are consistent with microglia responding to and participating in the ongoing neurodegeneration, and thus are found in any mouse models of neurodegenerative diseases characterised by neuronal loss [34]. Therefore, it is unclear to what extent microglia promote or respond to neurodegeneration, likely both, and we still do not have insight into how microglia participate in the onset of the disease.

In humans, microglial activation is a neuropathological feature of the disease and microglia

participate to the formation of the neuritic plaques, clustering around A β deposits (Figure 1H). Using a mathematical model, activated microglia have been placed after A β plaques but before tau pathology [6]. However, longitudinal studies of PET imaging using microglia, A β and tau ligands are necessary to confirm *in vivo* the dynamics of these events. In an unbiased elderly population, immunophenotyping of microglia using markers associated with specific microglial functions (Figure 2) has revealed that in AD microglia appear to lose motility associated proteins (e.g. Iba1), a key function in synaptic support [35] and change towards a more phagocytic phenotype (CD68, macrophage scavenging receptor (MSR)-A), partly driven by the APOE genotype [36]. This study highlighted that microglia were responding differently to A β and tau in participants with or without dementia and were able to adopt different functions relatively independently, emphasizing the likely coexistence of different microglial populations within the same brain. Interestingly, the brain environment reveals inflammatory heterogeneity, with a mixture of pro- and anti-inflammatory compounds, observed *post-mortem* in late stages of the disease [37, 30]. However in the early stages of AD, a more polarised inflammatory environment towards either pro- or anti-inflammatory profile was reported to be associated with different pathological severity [37], possibly reflecting different stages of the disease or different microglial populations.

The immune reactions are clearly complex in AD, with evidence of temporal changes of microglia. However, these studies lack information on the specific functions performed by microglia throughout the course of the disease. Microglia activation undergoes various stages, which have been traditionally classified into pro-inflammatory / detrimental (M1) or anti-inflammatory / protective (M2). However, there is increasing evidence that the M1/M2 division is somewhat artificial and even considered obsolete. Instead, microglia assume a continuum of activation states characterized by the expression of multitude of markers that overlap between M1 and M2 states [38], continuum which can evolve, potentially driving, the disease [37]. This complexity of microglial activation represents one of the main challenges to identify targets suitable for molecular imaging.

Molecular imaging targets for microglia in Alzheimer's disease and mild cognitive impairment (MCI) patients

Molecular imaging studies in AD have largely focused on visualising activated microglia, most commonly measured by elevated expression of translocator protein 18 kDa (TSPO), a five transmembrane domain protein mainly located in the outer mitochondrial membrane of microglia [39]. While mostly considered as a specific marker of microglial activation, TSPO has been found to be overexpressed in activated astrocytes [40, 41]. ~~TSPO presents some~~ One of the limitations associated with the use of TSPO is, especially its inability to distinguish between the different phenotypes expressed by ~~the cell~~ microglia, potentially lacking disease-specificity. These limitations have led to the search for alternative biological targets for imaging microglia, ~~including different microglial cell and mitochondria surface receptors~~. Some of the emerging tracers target P2X₇ receptors, cannabinoid receptor type 2 (CB2), cyclooxygenase (COX)-2, colony stimulating factor 1 receptor (CSF1R) and reactive oxygen species (reviewed in [39, 42], Figure 3). Although ~~substantial~~ progress has been made, most of the emerging tracers target only the pro-inflammatory (M1) phenotype of activated microglia, and several tracers have issues of limited specificity as they bind also to other cells such as astrocytes and endothelial cells. Among the most promising novel tracers are ~~those targeting the~~ purinergic receptors including P2X₇ selective towards M1 phenotype and overexpressed in AD brain, and P2Y₁₂ selective towards M2 phenotype and with reduced expression around A β plaques in AD brain [42]. Of note, P2Y₁₂ PET tracers are yet the only ones identified to

target the M2 anti-inflammatory phenotype and has been associated with physiological/homeostatic microglia.

Below we will review the human imaging studies aiming to characterize *in vivo* microglial activation in AD and MCI (mild cognitive impairment), both with TSPO and non-TSPO tracers.

PET studies using TSPO tracers

When reviewing the work ~~that has been~~ done on using PET tracers for TSPO, the literature shows divergent and sometimes conflicting results. This is partially due to different binding properties of the various PET tracers but also of the methodological issues when quantifying the PET signal.

The ^{11}C -labelled (*R*)-isomer of PK11195 is the best-characterised PET ligand for imaging activated microglia *in vivo*. In a pilot PET study in eight AD patients (median age 63.5 years, median MMSE 19.5) vs. 15 control subjects, increased ^{11}C -(*R*)-PK11195 binding potential (BP) was ~~seen-measured compared to 15 controls~~ in the inferior and middle temporal gyri, fusiform gyri, left parahippocampal gyrus, amygdala and posterior cingulate [43]. A ~~further-subsequent~~ study examined ^{11}C -(*R*)-PK11195 and ^{11}C -Pittsburgh compound B (^{11}C -PiB, a ligand for A β) BP in 13 AD patients (mean age 65.6 years, mean MMSE 21.2) using both region-of-interest (ROI) and voxel-based analysis. Significant increases in ^{11}C -(*R*)-PK11195 BP were ~~seen-found~~ in frontal, temporal, parietal and occipital association cortices, cingulate cortex and striatum ~~compared to controls~~, in a pattern that corresponded with areas of increased ^{11}C -PiB binding [44], connecting microglial activation to A β plaque deposition. Interestingly, ^{11}C -(*R*)-PK11195 binding in the posterior cingulate, frontal and parietal cortices, but not ^{11}C -PiB uptake ratio, was negatively correlated with MMSE [44]. This implied that microglia rather than A β deposition was the culprit for the cognitive decline, before the confirmation by the genetics of a role of the innate immunity in AD pathogenesis [45]. These findings were replicated Increased binding of ^{11}C -(*R*)-PK11195 in AD was by others also reported [46]. Another study using ~~as well as~~ the alternative TSPO tracer ^{11}C -DAA1106 [47] also detected increased signal in AD patients in all regions investigated but did not assess the link with the cognitive decline.

Assessment of Microglial activation has also been of particular interest ~~investigated~~ in patients with MCI to aim at exploring the kinetic and temporal association of the different neuropathological features. Our own group study of 12 MCI compared to 7 healthy volunteers, ROI analysis revealed increased ^{11}C -(*R*)-PK11195 binding in the posterior cingulate gyrus, parietal, occipital, frontal and temporal lobes as well as in the putamen (Figure 4A) (A. Gerhard, unpublished results). Interestingly, in this series the MCI patients that were either homo- or heterozygote for the ApoE ϵ 4 allele seemed to show higher binding than the ones with an ApoE ϵ 3/3. Our study links two risk factors for AD, immunity and APOE genotype. Study of ^{11}C -(*R*)-PK11195 and ^{11}C -PiB PET in 14 patients with amnesic MCI (mean MMSE 27.7), 22 with AD (mean MMSE 21.5) and 10 controls (mean MMSE 29.9) identified increased ^{11}C -(*R*)-PK11195 BP in frontal cortex of PiB-positive MCI patients ~~compared to controls~~ [48], but also observed MCI patients with either increased PK11195 or PiB signal. The authors propose microglial activation and A β deposition as two independent processes in AD. This might be the case, however, we can argue that the discrepancy, especially in the PiB-negative MCI patients, might be the consequence of different processes with some leading to another dementia than AD. ~~These results have also been confirmed and extended by our own group study of 12 MCI compared to 7 healthy volunteers, where ROI analysis revealed increased ^{11}C -(*R*)-PK11195 binding in the posterior cingulate gyrus, parietal, occipital, frontal and temporal lobes as well as the putamen compared with controls (Figure 4A) (A. Gerhard, unpublished results)~~. Interestingly, in this series the MCI patients that were either homo- or heterozygote for the ApoE ϵ 4 allele seemed to show higher binding than the ones with an ApoE 3/3. Nevertheless, a recent study confirmed the spatial association between the Examining the spatial correlation of ^{11}C -(*R*)-PK11195 binding and cortical

Aβ load as measured with ¹¹C-PiB in 42 MCI patients, ~~a positive correlation was found within subregions of frontal, parietal and temporal cortices, with an overlapped distribution.~~ ¹¹C-(R)-PK11195 PET revealed increased inflammation in a majority of Aβ-positive MCI cases, its cortical distribution overlapping that of Aβ deposition [49].

In contrast to the above listed positive studies, a study of six MCI patients (mean MMSE 19), six AD patients (mean MMSE 19) and five controls failed to find any differences in ¹¹C-(R)-PK11195 binding using ROI analysis, even when ¹¹C-PiB uptake was taken into account [50]. A further study failed to identify any significant group differences in PK11195 binding between controls, ~~and~~ AD and MCI patients using both ROI-based and voxel-based analysis approaches [51]. ~~Therefore, it~~ is not yet clear whether ~~this the disparities in the findings between the studies~~ is due to differences in methodology, or in the selection and clinical stage of patients.

~~As mentioned above, imaging of microglial activation using ¹¹C-(R)-PK11195 PET has several limitations, which have been summarized in a review of the field [52]. While PK11195 is thought to bind predominantly to activated microglia, increases in binding to activated astrocytes have been reported by some authors [53]. However, ³H-(R)-PK11195 binding in post-mortem tissue from patients with neuroinflammatory disorders correlated strongly with CD68-labelled phagocytic microglia, but not GFAP-labelled positive astrocytes, albeit with a lower binding affinity compared to the novel TSPO ligand ³H-DAA1106 [54]. A further potential limitation is that in vivo studies with ¹¹C-(R)-PK11195 generally display a relatively low signal-to-noise ratio [52].~~

~~The optimal-most appropriate method of analysis for PET data in neurodegenerative disorders is also the subject of debate, as the selection of a reference region to allow intensity normalization is difficult due to constitutive expression of TSPO within the brain and potentially very widespread pathology. Modified methods using kinetic analysis to identify a reference tissue cluster have been employed in the analysis of ¹¹C-(R)-PK11195 PET data in neurodegenerative disease [55]. Lastly, as a ¹¹C-labelled tracer ¹¹C-(R)-PK11195 has only a short half-life and necessitates a cyclotron on site for tracer production, impeding its use. These limitations have led to the development of novel TSPO ligands for PET imaging in neurodegenerative diseases with wider clinical application.~~

Over the last years, numerous novel radiotracers for ~~activated microglial activation~~ have been developed [56]. The compounds DAA1106 and PBR28 have been shown to have 10-fold higher *in vitro* affinity for TSPO compared to PK11195 [57, 58]. ¹¹C-DAA1106 has been shown to have higher BP in prefrontal, parietal, anterior cingulate and occipital cortex, striatum and cerebellum in a PET study of 10 AD patients ~~versus~~ 10 healthy controls, although partial volume effects could explain some of these changes [47]. A further study in seven MCI patients, 10 AD patients and 10 healthy controls ~~identified showed~~ increased ¹¹C-DAA1106 BP in temporoparietal cortex, anterior cingulate and striatum in ~~both~~ MCI and AD patients compared to controls [59]. ~~However, in contrast to the previous studies using PK11195, no difference in the DAA1106 bindings was observed between the MCI and AD patients. However This might be the consequence of, the finding of populations of high- and low-affinity binders for TSPO ligands other than ¹¹C-(R)-PK11195 has further complicating furthered the analysis of these data [58]. Thus, studies utilizing such ligands require analysis of TSPO binding affinity to correct for this factor. Of note, early-onset (<65 years) patients were detected to have greater ¹¹C-PBR28 binding of the ¹¹C-PBR28 ligand than late-onset patients in parietal cortex and striatum, and ¹¹C-PBR28 binding correlated with lower age of onset [60]. adding to the complexity of the interpretation of the TSPO data and our understanding of the role of microglia in AD.~~

~~Attempts at exploring T~~he time course of microglial activation was ~~performed investigated in patients with Aβ pathology~~ in a large prospective study including 64 patients with AD (prodromal AD n=38; AD dementia n=26) and 32 controls, ~~and used a~~ simple ratio method ~~was used~~ with cerebellar

grey matter as reference tissue to measure TSPO binding. The study ~~revealed~~showed that microglial activation appears at the prodromal and possibly at the preclinical stage of AD, and the authors concluded ~~from their results~~ that microglia might play an early protective role in the clinical progression of the disease ~~at these early stages~~ [61]. Subsequently the authors followed a proportion of the participants over two years and found that high initial ^{18}F -DPA-714 binding was correlated with a low subsequent increase of microglial activation and favourable clinical evolution, whereas the opposite profile was observed when initial ^{18}F -DPA-714 binding was low, independently of disease severity at baseline. They felt that their results support a pathophysiological model involving two distinct profiles of microglial activation signatures with different dynamics, which differentially impact on disease progression and may vary depending on patients rather than disease stages [62]. However without the use of ligand associated with already identified profile of microglia, as described previously, this remains speculative.

Only further clinical evaluations and direct comparisons with ^{11}C -(R)-PK11195 will show whether any of the 2nd and 3rd generation TSPO tracers are indeed superior in the clinical context. As there are known to be species differences in TSPO binding, *in vitro* and preclinical animal data do not always directly translate into clinical applications in humans [56].

PET studies using non-TSPO tracers for neuroinflammatory changes in AD

It is important to realise that TSPO expression is only one phenomenon within the complex process of microglial activation and currently effort goes into the development of *in vivo* imaging markers that can measure other pathways of this process. ~~However, d~~Developing and evaluating PET ligands is a lengthy process and currently only very few novel non-TSPO ligands are being used in a clinical context.

The cannabinoid type 2 receptor (CB2R) is expressed by immune cells ~~such as including~~ monocytes and macrophages. In the brain, CB2R is primarily found on microglia. ~~CB2R-Its~~ upregulation has been reported in animal models of AD, and ^{11}C -NE40 – a tracer for CB2R - has been evaluated in healthy controls and patients with AD. Surprisingly AD patients showed overall significantly lower CB2R binding than healthy controls and no relationship was found between regional or global A β load and CB2R availability, possibly because due to lower affinity of selectivity of ^{11}C -NE40 binds to CB2R with lower affinity and/or selectivity than to CB1R [63].

~~The $P2X_7$ receptor ($P2X_7R$) is an ATP-gated ion channel predominantly expressed on activated microglia.~~ ^{11}C -JNJ717 is, a selective $P2X_7R$ tracer, one of the ATP-gated ion channels expressed on activated microglia, was evaluated in healthy volunteers and Parkinson's disease (PD) patients where microglia are known to become activated as part of the neuropathological changes. No difference was found in binding between healthy controls and PD patients [64]. So far, no clinical studies have been conducted using this tracer in AD.

The colony-stimulating factor 1 receptor (CSF1R) might also be a very interesting target for neuroinflammation imaging and very recently preclinical data in a murine model of AD have been acquired [65], but no clinical studies have been conducted as of yet.

Astrocytes in the healthy brain

Astrocytes derive from heterogeneous populations of progenitor cells in the neuroepithelium. They adopt a star-like morphology and in humans form 20 to 40% of all glia [66]. Several populations of astrocytes cohabit in the adult brain [67] (Figure 5). In the grey matter, we find (i) the protoplasmic astrocytes characterised by highly branched bushy processes and located in the cortical grey matter; (ii) the primate-specific interlaminar astrocytes located in the superficial cortical layers I and II of the cortex and (iii) the varicose projection astrocytes in layers V and VI [67, 68]. The fibrous astrocytes

are mainly present in the white matter along the myelinated axons and exhibit long and straight processes [67].

Astrocytes are key element of brain homeostasis displaying numerous physiological functions. They are involved in: (i) neurodevelopment [69]; (ii) synaptic function [70]; (iii) energy metabolism [71]; (iv) the neurovascular unit via their processes [72]; and recently they were identified to be involved in (v) the circadian clock [73]. This large functional diversity is in keeping with the heterogeneous and pleomorphic astrocytes population throughout the brain. Glial fibrillary acidic protein (GFAP), an intermediate filament and major component of the astrocyte skeleton, is the most common marker to identify astrocytes, with its expression higher in fibrous than protoplasmic astrocytes [67]. However, it is now acknowledged that GFAP does not detect all astrocytes [74]. Other markers, based on the astrocyte functions, have been utilized sometimes in combination, to identify the different populations in humans including: the enzyme aldehyde dehydrogenase 1 family member L1 (Aldh1l1), calcium-binding protein S100B, the glutamate transporters excitatory amino-acid transporter (EAAT) 1 and 2 for the synaptic transmission, the enzyme glutamine synthetase, and the Aquaporin 4 expressed at astrocyte endfoot processes to regulate water homeostasis [75]. Novel astrocyte-specific markers are emerging from rodent studies such as CD44 [76], CD51 (integrin alpha V protein), CD63 (LAMP-3) and CD71 (transferrin receptor 1) [77].

Ageing modifies astrocytes including their morphology with the processes becoming shorter and thicker, increasing cell density and GFAP expression [78], together considered as common features of activated astrocytes. Therefore, this suggests that, like microglia, astrocytes become reactive with age. The molecular profile of aged astrocytes, defined from rodent brain, encompasses upregulation of the complement system (*C3* and *C4B*); major histocompatibility complex (*H2-D1* and *H2-K1*); cytokines/chemokines (*CXCL10* and *CXCL5*); peptidase inhibition (*Serpina3n*); alteration in lipid/cholesterol synthesis [79] and potentially the disruption of blood-brain barrier integrity and function [80].

To add to the complexity of the astrocyte population, subtypes of reactive astrocytes have been identified in mice giving rise to the A1 (neurotoxic) vs. A2 (neuroprotective) classification [81], with ageing driving the predominance of A1 astrocytes (characterised by the expression of C3) in rodent brain [79] (Table 3).

Astrocytes in Alzheimer's disease

Astrocytes participate to the neuroinflammatory processes by their properties to react to a range of pro and anti-inflammatory components [82]. Both microglia and astrocytes have roles in the phagocytosis of cell debris and A β , and in responding to damage [83]. ~~and~~ In addition, astrocytes participate in neuronal metabolic support as evidenced by preclinical studies [84]. In primary cultures of astrocytes, ~~Interestingly, exposure of astrocytes to soluble-A β_{25-35} led induce~~ to increased glucose uptake via glycolysis coupled to lactate release [85], ~~ing peptides into astrocytes significantly~~ altering their metabolic phenotype. This resulted ~~Exposure of astrocytes to soluble A β_{25-35} also led to~~ in increased astrocytic MAO-B expression, [86], one of the molecular targets to image astrocytes. ~~In~~ In a transgenic mouse model of AD, astrocytic MAO-B overexpression ~~resulted caused in~~ excess gamma-aminobutyric acid (GABA) and excitotoxic glutamate release, disrupting oxidativemodifying homeostasis and leading to cognitive deficits [87].

In humans, clusters of reactive astrocytes around A β plaques are a hallmark of AD [88, 89]. However, the spatial distribution of astrocytes is independent of plaque size, different from microglia whose number around plaques correlates to plaque size [89]. Neuropathological studies have demonstrated increased reactive astrocytes in the vicinity of plaques as the disease progresses, but are

unclear in determining whether astrocytes reaction is an early event [90, 91] or whether the cells play a role in the late stage of disease when dementia develops [92]. Nevertheless, imaging and *post-mortem* human studies have started to provide some clues on the dynamics of the astrocytic response in AD. GFAP expression is upregulated in AD [78], with A1 astrocytes forming the main population of the reactive cells in humans [93], consistent with a previous study highlighting variation in the pattern of GFAP, EAAT1, EAAT2 and S100B in relation to AD pathology [94]. Overall, evidence in the human brain supports astrocyte changes in AD as phenotypic rather than proliferative [95, 96], which has implications in terms of imaging.

Molecular imaging targets for astrocytes

Multiple molecular imaging markers are needed to visualize astrocytosis as illustrated in Figure 3, given that it is a highly dynamic process undergoing sequential protective (A2) and detrimental (A1) stages. There is increasing evidence that morphology and function are inter-related in astrocyte activation, with an initial hypertrophic phase characterized by the overexpression of different markers involving MAO-B, intermediate filaments including nestin, vimentin and GFAP [97] followed by an astrodegeneration phase characterized by atrophy, reduced branching and synaptic dysfunction, with reduced expression of markers such as Aquaporin-4 and glutamine synthetase.

Enzymes

Among few astrocyte PET tracers available, ^{11}C -deuterium-L-deprenyl (^{11}C -DED) binds to MAO-B, an enzyme overexpressed in activated astrocytes [98]. Autoradiography studies have demonstrated that ^3H -L-deprenyl binding overlaps with GFAP in AD and other neurodegenerative diseases [98-101], indicating a good level of specificity of MAO-B to activated astrocytes. Autoradiography data using ^{11}C -L-deprenyl in AD brain tissue showed the highest tracer uptake at the earliest Braak stages, suggesting early involvement of astrocytosis in AD [102]. ^3H -L-deprenyl had a different laminar pattern than that of A β deposition as measured by ^3H -PiB [103], but partly co-located with tau as measured by ^3H -THK5117 [104].

^{11}C -DED PET imaging has been used to investigate astrocytosis in neurodegenerative diseases including AD [105, 106], amyotrophic lateral sclerosis [107] and Creutzfeldt-Jakob disease [108]. Multitracer PET studies using ^{11}C -DED, ^{11}C -PiB and ^{18}F -fluorodeoxyglucose (^{18}F -FDG), have allowed investigating the spatio-temporal patterns of *in vivo* brain astrocytosis, fibrillar A β deposition, and glucose metabolism at different stages of disease progression. In these studies, significantly increased ^{11}C -DED binding was found in prodromal AD in comparison to healthy controls or AD dementia patients [106]. In autosomal-dominant AD, astrocytosis was observed at early presymptomatic stages using ^{11}C -DED PET [109]; longitudinally, A β plaque deposition (^{11}C -PiB) increased while astrocytosis (^{11}C -DED) declined [110]. Early astrocytosis preceding A β plaque deposition was replicated in transgenic AD mice [111].

Receptors

The imidazoline-2 binding sites (I $_2$ BS) are located on the mitochondrial membranes of astrocytes [112] and are involved in the regulation of GFAP expression [113]. An increase in *post-mortem* density of I $_2$ BS has been observed in AD brain [114]. The novel PET tracer ^{11}C -BU99008 has been characterized in preclinical species and demonstrated to be suitable to quantify cerebral I $_2$ BS density, as determined in rat [115], pig [116] and rhesus monkey [117]. More recently, ^{11}C -BU99008 was found to have good kinetic properties in healthy human brain, with low affinity to MAO-A/MAO-B [118]. Studies in MCI and AD patients are underway to compare the regional distribution of ^{11}C -

BU99008 with that of A β and ^{18}F -FDG PET retention [119].

Metabolic markers

^{18}F -FDG-PET hypometabolism has been traditionally considered a biomarker for neuronal injury and neurodegeneration. However, a recent preclinical study showed evidence that astrocytes ~~-, at least partially, can~~ contribute to ^{18}F -FDG-PET as measured in healthy rat brain, ~~challenging the long-held neurocentric interpretation of ^{18}F -FDG metabolism~~ [120]. This study adds support to the astrocyte-neuron lactate shuttle hypothesis initiated 20 years ago, that suggests that neuronal energy demands ~~in neurons-are~~ mostly met by lactate, originated in astrocytes and shuttled to neurons [121, 122]. Consistent with these preclinical findings, it was recently shown that longitudinal decline in astrogliosis, as measured by MAO-B expression, was correlated to progressive hypometabolism in autosomal-dominant AD mutation carriers [123], indicating that astrocytes may in part reflect metabolic activity in AD. The observed decline in the functional astrocyte marker MAO-B, potentially associated with ~~might thus reflect~~ reduced glucose demand by astrocytes, might represent ~~due to~~ astrodegeneration, a glial phenotype ~~observed characteristic of in~~ late stages of neurodegenerative diseases AD [97]. This link remains to be confirmed in a study associating ^{18}F -FDG imaging of sporadic AD patients with human post-mortem examination.

Other potential targets have been explored in preclinical studies, but *in vivo* studies in human are still rare. For example, the astrocyte-specific glutamate transporters GLT1 (in rodents) and EAAT2 (the equivalent to GLT1 in humans) were reduced in *post-mortem* tissue [124-126], indicating loss of function of astrocytes at late disease stages. Similarly, glutamine synthetase ~~(specific to astrocytes)~~ was observed to decline with age in a transgenic mouse model of AD, suggesting impairment disturbance in glutamate homeostasis with disease progression [127]. Another potential marker for astrocyte-related metabolic dysfunction is the impairment in GLUT1 (glucose transporter 1) protein expression, a glucose transporter predominantly expressed in astrocytes [128]. Interestingly, aerobic glycolysis, known to take place mostly in astrocytes, was observed to decline as tau accumulated in A β -positive cognitively-normal individuals [129], ~~suggesting supporting that~~ astrocyte dysfunction as an early event in ~~may be present from preclinical AD stages~~. These studies motivate the current research on PET imaging tracers that could target astrocyte-specific glutamate transporters in human brain including EAAT1/EAAT2 and GLAST (glutamate aspartate transporter). These studies will, that will greatly contribute to understanding the ~~role-contribution~~ of astrocytes ~~in metabolism to the~~ metabolic changes observed in AD ~~and other neurodegenerative diseases~~.

Emerging structural MRI and DTI imaging tools: Tracking morphological changes of activated astrocytes and microglia?

Microglia and astrocytes possess ramified morphologies, which under pathological conditions are modified towards a more amoeboid-like (microglia) or hypertrophic-like (astrocytes) as described above. These morphological changes have motivated the development of structural magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) imaging tools to incorporate into multimodal MRI/PET approaches, that would better investigate the complex neuroinflammatory changes in AD. Using MRI and DTI, a recent study proposed a model of grey matter changes in AD [130], in which an early presymptomatic phase of decreased cortical mean diffusivity (MD) and increased cortical thickness (CTh), hypothesized to reflect hypertrophy or glial cell swelling due to neuroinflammation, is followed by increased cortical mean diffusivity and decreased cortical thickness reflecting neurodegeneration. More recently, the direct relationship between structural vs. inflammatory changes were tested in autosomal-dominant AD (Vilaplana *et al.*, under review). In this

study, ¹¹C-DED binding had a negative association with MD and a positive association with CTh, suggesting that astrocyte activation and associated hypertrophy may underlie the observed reduction in MD and increases in CTh. Another recent study has found a positive correlation between microgliosis as measured by TSPO PET and CTh at the early MCI stage of AD [131], suggesting that neuroinflammation is accompanied by cortical swelling from early stages. In the same lines, new analysis techniques for DTI imaging allow extracting a measure of cell body size called “cellular diffusivity”, that is interpreted to reflect activated microglia or astrocytes [132]. These initial studies motivate further *in vivo* multimodal studies combining MRI, DTI and PET imaging to fully characterize the complex molecular and morphological dynamics of neuroinflammation across disease progression in AD.

Relationship between PET imaging of neuroinflammation vs. amyloid- β and tau proteinopathies

Recent preclinical evidence implies that glial activity could lead to tau deposition [133, 134]. It is still unclear whether the oligomeric forms of A β can cause the glial activation, which leads to tau formation and propagation throughout the cortex. Very few studies have imaged and compared inflammation and tau in human AD, and they support that inflammation is more strongly correlated to A β , likely preceding tau deposition [135-137]. However longitudinal studies are needed to confirm these results.

CSF and plasma biomarkers of neuroinflammation

One of the most promising and more extensively investigated CSF glial biomarker is YKL-40, a secreted glycoprotein expressed by microglia and astrocytes [138]. Recently, an increasing number of CSF biomarkers are being developed to track microglia and astrocyte activation, neuroinflammation and cerebrovascular dysfunction including YKL-40, sTREM2, IL-6, IL-7, IL-8, IL-15, IP-10, monocyte chemoattractant protein (MCP)-1, intercellular adhesion molecule (ICAM)-1, vascular adhesion molecule (VCAM)-1, placental growth factor, and fms-related tyrosine kinase 1 (Flt-1) [139, 140]. CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were increased in AD already from the preclinical and prodromal stages and were associated with CSF tau especially in A β -positive individuals. Interestingly their increase was associated to cortical thinning. Studies comparing neuroinflammation CSF and PET biomarkers are to our knowledge still lacking, and thus these studies will add very valuable knowledge in the near future.

Neuroinflammation biomarkers and clinical trials

There is an urgent need to develop biomarkers for characterizing multiple pathophysiological mechanisms including neuroinflammation [141]. Inflammation biomarkers are of interest in clinical trial design, due to their utility for patient stratification and to track biological effects of drugs. In this respect, the studies reviewed here motivate further research on the possible utility of neuroinflammation PET as well as structural MRI/DTI imaging measures, used alone or in combination, for their possible application as biomarkers in clinical trials. Consequently, it is essential to develop novel PET tracers that are more specific to astrocytes and to microglia, and that can selectively target their different inflammatory stages. Thus, translational studies *in post-mortem* human brain are necessary to characterise these profiles and to develop a solid knowledge about what these tracers are binding to.

Conclusion

To date, astrocytes have been investigated to a lesser extent than microglia for their role in AD; however recent papers have emphasized the importance of a bidirectional communication between microglia and astrocytes via physical contacts and secreted molecules. Microglia, the sensors of changes in homeostasis, are the primary immune cells of the brain, which also regulate the immune functions of astrocytes. Experimental studies in diverse neurodegenerative diseases imply that microglia define the functions of astrocytes, ranging from neuroprotective to neurotoxic. Conversely, astrocytes appear to regulate microglial phenotypes and functions including motility and phagocytosis [91]. Of note with this review, we also emphasise the gaps between the markers identified in preclinical and human studies, with the importance of phenotypes, and the choice of the imaging targets, highlighting the need for better translational research between these two areas.

Nevertheless, whether modulation of microglia/astrocyte cross-talk can ameliorate neurodegeneration in human AD remains to be demonstrated. Nevertheless, it is essential to increase our knowledge of the glial biology and of their interactions with the environment in a physiological/healthy context. This will identify targets to image glia which, whether in multimodal imaging studies or in combination with other parameters (fluid biomarkers), will clarify the involvement of glial cells in the course of the disease.

Compliance with Ethical Standards

Funding

Prof. Boche is supported by grants from the Alzheimer's Research UK, the British Neuropathological Society and the University of Southampton. Dr Gerhard is supported by a grant from the Medical Research Council (MRC), UK and the University of Manchester. Dr. Rodriguez-Vieitez is supported by grants from the Swedish Alzheimer Foundation (Alzheimerfonden), the Swedish Dementia Association (Demensfonden), Åke Wiberg Foundation, Gun and Bertil Stohne's Foundation, Gamla Tjänarinnor's Foundation, and the Karolinska Institutet foundations.

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical approval

Figure 4A: The study was approved by the local research and ethics committee (National Research Ethics Committee North West – Greater Manchester North) and permission to administer radiotracers was obtained from the Administration of Radioactive Substances Advisory Committee of the Department of Health (ARSAC), UK. Figure 4B: The PET imaging data presented in Figure 4B were collected as part of a previously published study [106]. In that study, ethical approval was obtained from the regional Human Ethics Committee of Stockholm and the Faculty of Medicine and Radiation Hazard Ethics Committee of Uppsala University Hospital, Sweden. The study was conducted in accordance with the principles of the Declaration of Helsinki and its subsequent revisions. For all PET imaging data presented in Figure 4B, all participants provided written informed consent to participate in the study, as previously published [106].

References

1. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* 2015;14(4):388-405. doi:10.1016/S1474-4422(15)70016-5.
2. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. *Nat Immunol.* 2015;16(3):229-36. doi:10.1038/ni.3102.
3. Vellas B, Bain LJ, Touchon J, Aisen PS. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018. *J Prev Alzheimers Dis.* 2019;6(3):198-203. doi:10.14283/jpad.2019.11.
4. Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. *JAMA Neurol.* 2019. doi:10.1001/jamaneurol.2019.1424.
5. Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. *Mol Neurodegener.* 2017;12(1):50. doi:10.1186/s13024-017-0192-x.
6. Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. *Nature communications.* 2019;10(1):409. doi:10.1038/s41467-018-08279-3.
7. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science.* 2010;330(6005):841-5. doi:science.1194637.
8. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity.* 2013;38(4):792-804. doi:10.1016/j.immuni.2013.04.004.
9. Bruttger J, Karram K, Wortge S, Regen T, Marini F, Hoppmann N et al. Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the Mammalian Central Nervous System. *Immunity.* 2015;43(1):92-106. doi:10.1016/j.immuni.2015.06.012.
10. Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P et al. Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain. *Cell reports.* 2017;18(2):391-405. doi:10.1016/j.celrep.2016.12.041.
11. Reu P, Khosravi A, Bernard S, Mold JE, Salehpour M, Alkass K et al. The Lifespan and Turnover of Microglia in the Human Brain. *Cell reports.* 2017;20(4):779-84. doi:10.1016/j.celrep.2017.07.004.
12. Dennis CV, Suh LS, Rodriguez ML, Kril JJ, Sutherland GT. Human adult neurogenesis across the ages: An immunohistochemical study. *Neuropathol Appl Neurobiol.* 2016;42(7):621-38. doi:10.1111/nan.12337.
13. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. *Nat Neurosci.* 2014;17(1):131-43. doi:10.1038/nn.3599.
14. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. *Acta Neuropathol.* 2001;101(3):249-55. doi:DOI 10.1007/s004010000284.
15. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science.* 2005;308(5726):1314-8. doi:1110647.
16. Squarzone P, Oller G, Hoeffel G, Pont-Lezica L, Rostaing P, Low D et al. Microglia modulate wiring of the embryonic forebrain. *Cell reports.* 2014;8(5):1271-9. doi:10.1016/j.celrep.2014.07.042.
17. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P et al. Synaptic pruning by microglia is necessary for normal brain development. *Science.* 2011;333(6048):1456-8. doi:10.1126/science.1202529.
18. Cunningham CL, Martinez-Cerdeno V, Noctor SC. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. *J Neurosci.* 2013;33(10):4216-33. doi:10.1523/JNEUROSCI.3441-12.2013.
19. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. *J Neurosci.* 2009;29(13):3974-80. doi:10.1523/JNEUROSCI.4363-08.2009.

20. Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. *PLoS Biol.* 2010;8(11):e1000527. doi:10.1371/journal.pbio.1000527.
21. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK et al. The microglial sensome revealed by direct RNA sequencing. *Nat Neurosci.* 2013;16(12):1896-905. doi:10.1038/nn.3554.
22. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.* 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039.
23. Lopez-Gonzalez I, Schluter A, Aso E, Garcia-Esparcia P, Ansoleaga B, Llorens F et al. Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice: Correlations With Plaques, Tangles, and Oligomeric Species. *J Neuropathol Exp Neurol.* 2015;74(4):319-44. doi:10.1097/NEN.0000000000000176.
24. Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. *J Neuroinflammation.* 2012;9:179-97. doi:1742-2094-9-179.
25. Davies DS, Ma J, Jegathees T, Goldsbury C. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer's disease. *Brain Pathol.* 2016. doi:10.1111/bpa.12456.
26. Streit WJ. Microglial senescence: does the brain's immune system have an expiration date? *Trends Neurosci.* 2006;29(9):506-10.
27. Olah M, Patrick E, Villani AC, Xu J, White CC, Ryan KJ et al. A transcriptomic atlas of aged human microglia. *Nature communications.* 2018;9(1):539. doi:10.1038/s41467-018-02926-5.
28. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. *Nat Rev Neurol.* 2014;10(4):217-24. doi:10.1038/nrneurol.2014.38.
29. Neher JJ, Cunningham C. Priming Microglia for Innate Immune Memory in the Brain. *Trends Immunol.* 2019. doi:10.1016/j.it.2019.02.001.
30. Rakic S, Hung YMA, Smith M, So D, Tayler HM, Varney W et al. Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. *Acta neuropathologica communications.* 2018;6(1):88. doi:10.1186/s40478-018-0592-3.
31. Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, Jain G et al. Innate immune memory in the brain shapes neurological disease hallmarks. *Nature.* 2018;556(7701):332-8. doi:10.1038/s41586-018-0023-4.
32. Norden DM, Godbout JP. Microglia of the aged brain: primed to be activated and resistant to regulation. *Neuropathol Appl Neurobiol.* 2013;39(1):19-34. doi:10.1111/j.1365-2990.2012.01306.x.
33. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. *Cell.* 2017;169(7):1276-90.e17. doi:10.1016/j.cell.2017.05.018.
34. Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. *Immunity.* 2017;47(3):566-81.e9. doi:10.1016/j.immuni.2017.08.008.
35. Akiyoshi R, Wake H, Kato D, Horiuchi H, Ono R, Ikegami A et al. Microglia Enhance Synapse Activity to Promote Local Network Synchronization. *eNeuro.* 2018;5(5). doi:10.1523/eneuro.0088-18.2018.
36. Minett T, Classey J, Matthews FE, Fahrenhold M, Taga M, Brayne C et al. Microglial immunophenotype in dementia with Alzheimer's pathology. *J Neuroinflamm.* 2016;13(1):135-45. doi:10.1186/s12974-016-0601-z.
37. Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM. Neuroinflammatory phenotype in early Alzheimer's disease. *Neurobiol Aging.* 2013;34(4):1051-9. doi:10.1016/j.neurobiolaging.2012.09.012.
38. Boche D, Perry VH, Nicoll JA. Activation patterns of microglia and their identification in the human brain. *Neuropathol Appl Neurobiol.* 2013;39(1):3-18. doi:10.1111/nan.12011.
39. Albrecht DS, Granziera C, Hooker JM, Loggia ML. In Vivo Imaging of Human Neuroinflammation. *ACS Chem Neurosci.* 2016;7(4):470-83. doi:10.1021/acschemneuro.6b00056.
40. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. *Neuropathol Appl Neurobiol.* 2009;35(3):306-28. doi:10.1111/j.1365-2990.2008.01006.x.

41. Lavis S, Guillemier M, Herard AS, Petit F, Delahaye M, Van Camp N et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012;32(32):10809-18. doi:10.1523/JNEUROSCI.1487-12.2012.
42. Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N. Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. *Mol Imaging*. 2018;17:1536012118792317. doi:10.1177/1536012118792317.
43. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE et al. In-vivo measurement of activated microglia in dementia. *Lancet*. 2001;358(9280):461-7. doi:S0140-6736(01)05625-2.
44. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. *Neurobiol Dis*. 2008;32(3):412-9. doi:10.1016/j.nbd.2008.08.001.
45. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS One*. 2010;5(11):e13950. doi:10.1371/journal.pone.0013950.
46. Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2011;38(2):343-51. doi:10.1007/s00259-010-1612-0.
47. Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. *Biological psychiatry*. 2008;64(10):835-41. doi:10.1016/j.biopsych.2008.04.021.
48. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R et al. Microglial activation and amyloid deposition in mild cognitive impairment: A PET study. *Neurology*. 2009;72(1):56-62. doi:10.1212/01.wnl.0000338622.27876.0d.
49. Parbo P, Ismail R, Hansen KV, Amidi A, Marup FH, Gottrup H et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. *Brain*. 2017;140(7):2002-11. doi:10.1093/brain/awx120.
50. Wiley CA, Lopresti BJ, Venetis S, Price J, Klunk WE, DeKosky ST et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. *Archives of neurology*. 2009;66(1):60-7. doi:10.1001/archneurol.2008.511.
51. Schuitmaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF et al. Microglial activation in Alzheimer's disease: an (R)-[(11)C]PK11195 positron emission tomography study. *Neurobiology of aging*. 2012. doi:10.1016/j.neurobiolaging.2012.04.021.
52. Venetis S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/macrophages in the brain. *Glia*. 2012. doi:10.1002/glia.22357.
53. Hazell AS, Desjardins P, Butterworth RF. Chronic exposure of rat primary astrocyte cultures to manganese results in increased binding sites for the 'peripheral-type' benzodiazepine receptor ligand 3H-PK 11195. *Neuroscience letters*. 1999;271(1):5-8.
54. Venetis S, Wang G, Nguyen J, Wiley CA. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. *Journal of neuropathology and experimental neurology*. 2008;67(10):1001-10. doi:10.1097/NEN.0b013e318188b204.
55. Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2007;48(1):158-67.
56. Chauveau F, Boutin H, Van Camp N, Dolle F, Tavittian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. *European journal of nuclear medicine and molecular imaging*. 2008;35(12):2304-19. doi:10.1007/s00259-008-0908-9.
57. Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom M et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. *J Cereb Blood Flow Metab*. 2010;30(9):1608-18. doi:10.1038/jcbfm.2010.63.

58. Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2011;52(1):24-32. doi:10.2967/jnumed.110.079459.
59. Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(11)C]DAA1106. *Psychiatry research*. 2012. doi:10.1016/j.psychresns.2011.08.013.
60. Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. *Brain*. 2013;136(Pt 7):2228-38. doi:10.1093/brain/awt145.
61. Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA et al. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. *Brain*. 2016;139(Pt 4):1252-64. doi:10.1093/brain/aww017.
62. Hamelin L, Lagarde J, Dorothee G, Potier MC, Corlier F, Kuhnast B et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. *Brain*. 2018;141(6):1855-70. doi:10.1093/brain/awy079.
63. Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, Van Laere K. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2016. doi:10.1007/s00259-016-3457-7.
64. Van Weehaeghe D, Koole M, Schmidt ME, Deman S, Jacobs AH, Souche E et al. [(11)C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers. *Eur J Nucl Med Mol Imaging*. 2019. doi:10.1007/s00259-019-04369-6.
65. Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). *Proc Natl Acad Sci U S A*. 2019;116(5):1686-91. doi:10.1073/pnas.1812155116.
66. von Bartheld CS, Bahney J, Herculano-Houzel S. The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting. *J Comp Neurol*. 2016;524(18):3865-95. doi:10.1002/cne.24040.
67. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F et al. Uniquely hominid features of adult human astrocytes. *J Neurosci*. 2009;29(10):3276-87. doi:10.1523/jneurosci.4707-08.2009.
68. Vassilev F, Dossi E, Rouach N. Human astrocytes: structure and functions in the healthy brain. *Brain structure & function*. 2017;222(5):2017-29. doi:10.1007/s00429-017-1383-5.
69. Farhy-Tselnicker I, Allen NJ. Astrocytes, neurons, synapses: a tripartite view on cortical circuit development. *Neural Development*. 2018;13(1):7. doi:10.1186/s13064-018-0104-y.
70. Santello M, Toni N, Volterra A. Astrocyte function from information processing to cognition and cognitive impairment. *Nat Neurosci*. 2019;22(2):154-66. doi:10.1038/s41593-018-0325-8.
71. Prebil M, Jensen J, Zorec R, Kreft M. Astrocytes and energy metabolism. *Archives of physiology and biochemistry*. 2011;117(2):64-9. doi:10.3109/13813455.2010.539616.
72. Mishra A, Reynolds JP, Chen Y, Gourine AV, Rusakov DA, Attwell D. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles. *Nat Neurosci*. 2016;19(12):1619-27. doi:10.1038/nn.4428.
73. Brancaccio M, Edwards MD, Patton AP, Smyllie NJ, Chesham JE, Maywood ES et al. Cell-autonomous clock of astrocytes drives circadian behavior in mammals. *Science*. 2019;363(6423):187-92. doi:10.1126/science.aat4104.
74. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. *Acta Neuropathol*. 2010;119(1):7-35. doi:10.1007/s00401-009-0619-8.
75. Szu JJ, Binder DK. The Role of Astrocytic Aquaporin-4 in Synaptic Plasticity and Learning and Memory. *Front Integr Neurosci*. 2016;10:8. doi:10.3389/fnint.2016.00008.
76. Sosunov AA, Wu X, Tsankova NM, Guilfoyle E, McKhann GM, 2nd, Goldman JE. Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain. *J Neurosci*. 2014;34(6):2285-98. doi:10.1523/jneurosci.4037-13.2014.

77. John Lin CC, Yu K, Hatcher A, Huang TW, Lee HK, Carlson J et al. Identification of diverse astrocyte populations and their malignant analogs. *Nat Neurosci.* 2017;20(3):396-405. doi:10.1038/nn.4493.
78. Jyothi HJ, Vidyadhara DJ, Mahadevan A, Philip M, Parmar SK, Manohari SG et al. Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta. *Neurobiol Aging.* 2015;36(12):3321-33. doi:10.1016/j.neurobiolaging.2015.08.024.
79. Clarke LE, Liddelow SA, Chakraborty C, Munch AE, Heiman M, Barres BA. Normal aging induces A1-like astrocyte reactivity. *Proc Natl Acad Sci U S A.* 2018;115(8):E1896-e905. doi:10.1073/pnas.1800165115.
80. Goodall EF, Wang C, Simpson JE, Baker DJ, Drew DR, Heath PR et al. Age-associated changes in the blood-brain barrier: comparative studies in human and mouse. *Neuropathol Appl Neurobiol.* 2018;44(3):328-40. doi:10.1111/nan.12408.
81. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG et al. Genomic analysis of reactive astrogliosis. *J Neurosci.* 2012;32(18):6391-410. doi:10.1523/jneurosci.6221-11.2012.
82. Sofroniew MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. *The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.* 2014;20(2):160-72. doi:10.1177/1073858413504466.
83. Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. *Exp Neurol.* 2012;236(1):1-5. doi:10.1016/j.expneurol.2012.04.021.
84. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. *Nat Med.* 2003;9(4):453-7. doi:10.1038/nm838.
85. Allaman I, Gavillet M, Belanger M, Laroche T, Viertl D, Lashuel HA et al. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. *J Neurosci.* 2010;30(9):3326-38. doi:10.1523/JNEUROSCI.5098-09.2010.
86. Song W, Zhou LJ, Zheng SX, Zhu XZ. Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. *Acta Pharmacol Sin.* 2000;21(6):557-63.
87. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. *Nat Med.* 2014;20(8):886-96. doi:10.1038/nm.3639.
88. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. *J Neuroimmunol.* 1989;24(3):173-82.
89. Serrano-Pozo A, Muzikansky A, Gomez-Isla T, Growdon JH, Betensky RA, Frosch MP et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. *J Neuropathol Exp Neurol.* 2013;72(6):462-71. doi:10.1097/NEN.0b013e3182933788.
90. Pike CJ, Cummings BJ, Cotman CW. Early association of reactive astrocytes with senile plaques in Alzheimer's disease. *Exp Neurol.* 1995;132(2):172-9.
91. Jha MK, Kim JH, Song GJ, Lee WH, Lee IK, Lee HW et al. Functional dissection of astrocyte-secreted proteins: Implications in brain health and diseases. *Prog Neurobiol.* 2018;162:37-69. doi:10.1016/j.pneurobio.2017.12.003.
92. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. *Neurobiol Aging.* 2003;24(2):321-31.
93. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L et al. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature.* 2017;541(7638):481-7. doi:10.1038/nature21029.
94. Simpson JE, Ince PG, Haynes LJ, Theaker R, Gelsthorpe C, Baxter L et al. Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. *Neuropathol Appl Neurobiol.* 2010;36(1):25-40. doi:10.1111/j.1365-2990.2009.01030.x.
95. Serrano-Pozo A, Gomez-Isla T, Growdon JH, Frosch MP, Hyman BT. A Phenotypic Change But Not Proliferation Underlies Glial Responses in Alzheimer Disease. *Am J Pathol.* 2013. doi:S0002-9440(13)00210-1.
96. Marlatt MW, Bauer J, Aronica E, van Haastert ES, Hoozemans JJ, Joels M et al. Proliferation in the Alzheimer hippocampus is due to microglia, not astroglia, and occurs at sites of amyloid deposition. *Neural Plast.* 2014;2014:693851. doi:10.1155/2014/693851.

97. De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. *Cell*. 2016;164(4):603-15. doi:10.1016/j.cell.2015.12.056.
98. Ekblom J, Jossan SS, Bergstrom M, Orelund L, Walum E, Aquilonius SM. Monoamine oxidase-B in astrocytes. *Glia*. 1993;8(2):122-32. doi:10.1002/glia.440080208.
99. Ekblom J, Jossan SS, Orelund L, Walum E, Aquilonius SM. Reactive gliosis and monoamine oxidase B. *J Neural Transm Suppl*. 1994;41:253-8.
100. Jossan SS, Ekblom J, Aquilonius SM, Orelund L. Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography. *J Neural Transm Suppl*. 1994;41:243-8.
101. Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang LC, Boileau I et al. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. *Brain*. 2017;140(9):2460-74. doi:10.1093/brain/awx172.
102. Gulyas B, Pavlova E, Kasa P, Gulya K, Bakota L, Varszegi S et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. *Neurochem Int*. 2011;58(1):60-8. doi:10.1016/j.neuint.2010.10.013.
103. Marutle A, Gillberg PG, Bergfors A, Yu W, Ni R, Nennesmo I et al. (3)H-deprenyl and (3)H-PIB autoradiography show different laminar distributions of astroglia and fibrillar beta-amyloid in Alzheimer brain. *J Neuroinflammation*. 2013;10:90. doi:10.1186/1742-2094-10-90.
104. Lemoine L, Saint-Aubert L, Nennesmo I, Gillberg PG, Nordberg A. Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography. *Scientific reports*. 2017;7:45496. doi:10.1038/srep45496.
105. Santillo AF, Gambini JP, Lannfelt L, Langstrom B, Ulla-Marja L, Kilander L et al. In vivo imaging of astrogliosis in Alzheimer's disease: an (1)(1)C-L-deuteriodeprenyl and PIB PET study. *Eur J Nucl Med Mol Imaging*. 2011;38(12):2202-8. doi:10.1007/s00259-011-1895-9.
106. Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B et al. Evidence for astrogliosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2012;53(1):37-46. doi:10.2967/jnumed.110.087031.
107. Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius SM et al. Evidence for astrogliosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. *J Neurol Sci*. 2007;255(1-2):17-22. doi:10.1016/j.jns.2007.01.057.
108. Engler H, Nennesmo I, Kumlien E, Gambini JP, Lundberg P, Savitcheva I et al. Imaging astrogliosis with PET in Creutzfeldt-Jakob disease: case report with histopathological findings. *Int J Clin Exp Med*. 2012;5(2):201-7.
109. Scholl M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S et al. Early astrogliosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. *Scientific reports*. 2015;5:16404. doi:10.1038/srep16404.
110. Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Scholl M et al. Diverging longitudinal changes in astrogliosis and amyloid PET in autosomal dominant Alzheimer's disease. *Brain : a journal of neurology*. 2016;139(Pt 3):922-36. doi:10.1093/brain/awv404.
111. Rodriguez-Vieitez E, Ni R, Gulyas B, Toth M, Haggkvist J, Halldin C et al. Astrogliosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. *European journal of nuclear medicine and molecular imaging*. 2015;42(7):1119-32. doi:10.1007/s00259-015-3047-0.
112. Regunathan S, Feinstein DL, Reis DJ. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. *J Neurosci Res*. 1993;34(6):681-8. doi:10.1002/jnr.490340611.
113. Olmos G, Alemany R, Escriba PV, Garcia-Sevilla JA. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. *Br J Pharmacol*. 1994;111(4):997-1002. doi:10.1111/j.1476-5381.1994.tb14842.x.
114. Garcia-Sevilla JA, Escriba PV, Guimon J. Imidazoline receptors and human brain disorders. *Ann N Y Acad Sci*. 1999;881:392-409.
115. Tyacke RJ, Fisher A, Robinson ES, Grundt P, Turner EM, Husbands SM et al. Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand,

BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole), for the imidazoline(2) binding site. *Synapse*. 2012;66(6):542-51. doi:10.1002/syn.21541.

116. Kealey S, Turner EM, Husbands SM, Salinas CA, Jakobsen S, Tyacke RJ et al. Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2013;54(1):139-44. doi:10.2967/jnumed.112.108258.

117. Parker CA, Nabulsi N, Holden D, Lin SF, Cass T, Labaree D et al. Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2014;55(5):838-44. doi:10.2967/jnumed.113.131854.

118. Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J et al. Evaluation of (11)C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2018. doi:10.2967/jnumed.118.208009.

119. Fan Z, Calsolaro V, Mayers J, Tyacke R, Venkataraman A, Femminella GD et al. Relationship between astrocyte activation using [11C]BU99008 PET, glucose metabolism and amyloid in Alzheimer's disease: A dementia platform UK experimental medicine study. *Alzheimer's & Dementia*. 2018;14(7):P1640. doi:10.1016/j.jalz.2018.06.2999.

120. Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI et al. [18F]FDG PET signal is driven by astroglial glutamate transport. *Nature neuroscience*. 2017;20(3):393-5. doi:10.1038/nn.4492.

121. Magistretti PJ, Pellerin L. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. *Mol Psychiatry*. 1996;1(6):445-52.

122. Pellerin L, Pellegrini G, Bittar PG, Charnay Y, Bouras C, Martin JL et al. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. *Dev Neurosci*. 1998;20(4-5):291-9. doi:10.1159/000017324.

123. Carter SF, Chiotis K, Nordberg A, Rodriguez-Vieitez E. Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2019;46(2):348-56. doi:10.1007/s00259-018-4217-7.

124. Acosta C, Anderson HD, Anderson CM. Astrocyte dysfunction in Alzheimer disease. *Journal of neuroscience research*. 2017. doi:10.1002/jnr.24075.

125. Hefendehl JK, LeDue J, Ko RW, Mahler J, Murphy TH, MacVicar BA. Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Abeta plaques by iGluSnFR two-photon imaging. *Nature communications*. 2016;7:13441. doi:10.1038/ncomms13441.

126. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. *Ann Neurol*. 1996;40(5):759-66. doi:10.1002/ana.410400512.

127. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission? *Mol Neurodegener*. 2011;6:55. doi:10.1186/1750-1326-6-55.

128. Pascual JM, Van Heertum RL, Wang D, Engelstad K, De Vivo DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. *Ann Neurol*. 2002;52(4):458-64. doi:10.1002/ana.10311.

129. Vlassenko AG, Gordon BA, Goyal MS, Su Y, Blazey TM, Durbin TJ et al. Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. *Neurobiol Aging*. 2018;67:95-8. doi:10.1016/j.neurobiolaging.2018.03.014.

130. Montal V, Vilaplana E, Alcolea D, Pegueroles J, Pasternak O, Gonzalez-Ortiz S et al. Cortical microstructural changes along the Alzheimer's disease continuum. *Alzheimers Dement*. 2018;14(3):340-51. doi:10.1016/j.jalz.2017.09.013.

131. Femminella GD, Dani M, Wood M, Fan Z, Calsolaro V, Atkinson R et al. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. *Neurology*. 2019;92(12):e1331-e43. doi:10.1212/WNL.00000000000007133.

132. Wang Q, Wang Y, Liu J, Sutphen CL, Cruchaga C, Blazey T et al. Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. *Neuroimage Clin*. 2019;22:101767. doi:10.1016/j.nicl.2019.101767.

133. Park J, Wetzel I, Marriott I, Dreau D, D'Avanzo C, Kim DY et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease. *Nat Neurosci*. 2018;21(7):941-51. doi:10.1038/s41593-018-0175-4.
134. Sosna J, Philipp S, Albay R, 3rd, Reyes-Ruiz JM, Baglietto-Vargas D, LaFerla FM et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease. *Mol Neurodegener*. 2018;13(1):11. doi:10.1186/s13024-018-0244-x.
135. Terada T, Yokokura M, Obi T, Bunai T, Yoshikawa E, Ando I et al. In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer's disease. *J Neurol*. 2019. doi:10.1007/s00415-019-09400-2.
136. Parbo P, Ismail R, Sommerauer M, Stokholm MG, Hansen AK, Hansen KV et al. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. *Neurobiol Dis*. 2018;117:211-6. doi:10.1016/j.nbd.2018.06.004.
137. Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R et al. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. *Brain*. 2018;141(9):2740-54. doi:10.1093/brain/aww188.
138. Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martin-Paniello C, Clarimon J, Belbin O et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. *J Neuroinflammation*. 2017;14(1):118. doi:10.1186/s12974-017-0893-7.
139. Falcon C, Monte-Rubio GC, Grau-Rivera O, Suarez-Calvet M, Sanchez-Valle R, Rami L et al. CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. *Neuroimage Clin*. 2019;23:101801. doi:10.1016/j.nicl.2019.101801.
140. Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. *Neurology*. 2018;91(9):e867-e77. doi:10.1212/WNL.0000000000006082.
141. Mattsson N, Carrillo MC, Dean RA, Devous MD, Sr., Nikolcheva T, Pesini P et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. *Alzheimers Dement (Amst)*. 2015;1(4):412-9. doi:10.1016/j.dadm.2015.09.001.

Legends

Figure 1. Illustration of different microglial morphologies in human brain identified with Iba1. (A-G) From ramified to ameboid microglia; (H) cluster of microglia around amyloid plaques as observed only in Alzheimer's disease. Counterstaining Haematoxylin, scale bar = 30 μ m

Figure 2. Microglial proteins expressed in human brain and associated with different functions: Iba1 (Motility); CD68 (phagocytosis); HLA-DR (antigen presentation); CD64 (Fc γ RI high-affinity activating receptor reflecting presence of immunoglobulins); P2_{Y12} (homeostasis); CD16 (Fc γ RIII low-affinity activating receptor for immune complexes). Counterstaining Haematoxylin, scale bar = 30 μ m

Figure 3. Cartoon illustrating emerging targets and PET tracers for the selective *in vivo* visualisation of activated microglia and astrocytes in Alzheimer's disease.

Figure 4. (A) Parametric 11C-(R)-PK11195 PET images of microglial activation in one MCI patient (upper row) and one healthy volunteer (lower row); PET images are displayed on each subject's respective T1-weighted MRI scan normalized to the SPM5 T1 brain template and the colour bar indicates non-displaceable binding potential (BPND) values. (B) Parametric 11C-deuterium-L-deprenyl PET images of astrocyte activation in one A β -positive MCI patient (upper row) and one healthy volunteer (lower row); PET images are displayed on each subject's respective T1-weighted MRI scan normalized to the SPM5 T1 brain template and the colour bar indicates modified-reference (cerebellar grey matter) Patlak slope values.

Figure 5. GFAP-positive astrocytes in human brain observed (A-B) in the grey matter; (C-D) with the endfeet of the processes forming a component of the blood-brain barrier; and (E-F) in the white matter. Counterstaining: Haematoxylin, scale bar = 50 μ m

Table 1. Microglial markers identified from rodent models and human studies

| Phenotype | Mouse (<i>gene, protein</i>) | Human (<i>gene, protein</i>) | Morphology[142] |
|--|--|--|---|
| Homeostatic, physiological status[13, 36, 143, 33, 34] | <i>Tgfb1r, Smad3, C1qa, C1qb, Cst3, Csf1r, Ctsd, Ctss, Cx3cr1, Entpd1 Fcrls, Hexb, Olfm13, P2y12, Tmem119, Tmsb4x, Sparc,</i> | TMEM119 P2Y12 CX3CR1 <i>Fcrls, C1qa, Pros1, Merlk, Gas6</i> Iba1 | Ramified with fine processes |
| Ageing[24, 32] | MHC class II Complement CR3 (CD11b) CD68, CD11c TLR members CD86 | FcγRs (CD64, CD32, CD16b) MHC class II (<i>HLA</i> subtypes, HLA-DR) Complement (<i>C1qA, C1qB, C1qC, C1s, C3, C3AR1, C4, C5, C5AR1</i>), <i>C1QBP, CFH, CFHR1, clusterin</i> TLR members (, <i>TLR2, TLR4, TLR5, MYD88</i>) <i>Calprotectin (S10A8, S100A9)</i> , CD14 <i>IRAK3, SOCS3</i> Inflammasome (<i>Casp1, TXNIP, PANX1, PANX2</i>) Chemokines (<i>CCRI, CXCL5, CXCL16</i>) CD68, CD11b | Ramified Less ramified with shorter and thicker processes |
| Alzheimer's disease[24, 36, 144, 33, 34, 30] | MGNd profile <i>Apoe, Trem2, Tyrobp, Axl, Clec7a, Ccl2, Csf1, Itgax, Lilrb4, Lgal3, Gpnmb, Fabp5, Spp1</i> DAM profile <i>Apoe, Trem2, Tyrobp, Axl, B2m, Fth1, Lyz2, Ctsb, Ctsd, Ctsl, Cst7, Csf1, Ccl6, Lpl, Cd9, Itgax, Clec7a, Lilrb4, Timp2</i> | FcγRs (CD64, CD32b, CD16b) MHC II (HLA-DR, DP, DQ) Complement (<i>C4, C3AR1, C5AR1</i>) <i>S100A8</i> <i>CSFR1</i> Chemokines (<i>CXCL16, CCR2</i>) TLR (<i>TLR2, TLR4, TLR5, TLR7</i>) CD68, CHI3L1, IL4R, MSR-A | Ramified Less ramified with shorter and thicker processes Ameboid shape (round shape with no processes) |

Underlined, common genes identified in both mouse microglial profiles.

Apoe: Apolipoprotein; Axl: Tyrosine-protein kinase receptor ; B2m: beta-2 microglobulin ; C1qA: Complement C1q subcomponent A C1QBP: C1q binding protein; C3AR1: Complement component 3a receptor 1; C5AR1: Complement component 5a receptor 1; Casp1: caspase 1; Clec7: C-type lectin domain family 7; CCR: Chemokine (C-C motif) receptor type; CHI3L1: Chitinase-3 Like-1; CXCL: Chemokine (C-X-C motif) ligand; Cx3cr1: CX3C chemokine receptor 1 (fractalkine receptor); CFH: Complement Factor-H; CFHR1: Complement Factor H Related 1 CR3: Complement receptor 3; Cst3: Cystatin; Ctsd: Cathepsin D; Ctsl: Cathepsin L; Ctss: Cathepsin S Csf1r: Colony stimulating factor 1 receptor; Entpd1: Ectonucleoside triphosphate diphosphohydrolase 1; Fabp5: Fatty acid binding protein 5; FcγR: Fcγ receptor; Fcrls: Fc receptor-like S; Fth1: Ferritin heavy chain 1; GAS6: growth arrest-specific 6; Gpnmb: Glycoprotein Nmb; GPR34: G protein-coupled receptor 34; HLA: Human leucocyte antigen; Hexb: Beta-hexosaminidase subunit beta; Iba1: Ionized calcium binding adaptor molecule 1; IRAK3: Interleukin 1

receptor associated kinase 3; Itgax: Integrin alpha X; IRAK3: Interleukin-1 receptor associated kinase 3; Lilrb4: Leukocyte Immunoglobulin Like Receptor B4; Lgal3: Galectin-3; Lpl: lipoprotein lipase; Lyz2: Lysozyme 2; MERTK: C-mer proto-oncogene tyrosine kinase; MHC: Major histocompatibility complex; MSR: Macrophage scavenger receptor; MYD88: myeloid differentiation primary response 88; PAX: Pannexin; Olfr13: Olfactomedin Like 3; P2y12: Purinergic receptor P2Y12; Pros1: Protein S; S100A8: S100 calcium-binding protein A8; Smad3: SMAD family member 3; SOCS3: Suppressor of cytokine signaling 3; Sparc: Secreted protein acidic and cysteine rich; Spp1: Secreted phosphoprotein 1; Timp2: Metalloproteinase inhibitor 2; Tgfb1: Transforming Growth Factor Beta Receptor 1 ; TLR: Toll-like receptor; TMEM: Transmembrane protein; Tmsb4x: Thymosin Beta 4 X-Linked; Tyrobp: TYRO Protein Tyrosine Kinase Binding Protein; Trem2: triggering receptor expressed on myeloid cells 2; TXNIP: Thioredoxin-interacting protein


Table 2. Definitions of the different microglial phenotypes

| Status | Definition |
|---|--|
| Physiological / Homeostatic | Microglia in an immune stimulus-free environment. |
| Primed microglia (one immune stimulus) | Prolonged and exaggerated increased immune response due to microglia already activated by an initial event. |
| Trained microglia (repetitive immune stimuli) | Increased microglial responses following priming. |
| Immune memory | Long-term consequences of trained microglia inducing cell reprogramming. This leads to either increased (primed) or decreased (tolerant) immune responses. |

Table 3. The different phenotypes acquired by the astrocytes

| Phenotype | Protein (<i>gene</i>) | Function |
|---|--|--|
| Homeostatic/physiological status Human brain | GFAP Aldh1l1 S100B EAAT1, EEAT2 AQP4 | Structural protein (intermediate filament) Formate oxidation Calcium binding protein Glutamate transporters Water transporter |
| A1 (neuroinflammation “neurotoxic”) from rodent brain[93, 79] | Complement C3 (<i>C3</i>) Complement C1-inhibitor (<i>Serping</i>) GGTA1 (<i>GGTA1</i>) Interferon-inducible GTPase1 (<i>Ligp1</i>) Glycerol-1-phosphate phosphohydrolase 2 (<i>Gpp2</i>) Fibulin-5 (<i>Fbln5</i>) FKBP5 (<i>Fkbp5</i>) PSMB8 (<i>Psmb8</i>) Serglycin (<i>Srgn</i>) Amigo2 (<i>Amigo2</i>) | Central role in complement activation Inhibition of the complement system (belongs to serpin superfamily) Glycosphingolipid biosynthesis Resistance to intracellular pathogens Glycerol biosynthesis Maintenance of the vessel wall after injury Role in immunoregulation and cellular processes involved in protein folding and trafficking Participate in the immunoproteasomes Mediator of granule-mediated apoptosis May contribute to signal transduction |
| A2 (ischemia “neuroprotective”) from rodent brain [93, 79] | Cardiotrophin-like cytokine factor 1 (<i>Clcf1</i>) Keratinocyte transglutaminase (<i>Tgm1</i>) Pentraxin 3 (<i>Ptx3</i> , TNF-inducible gene 14 protein) S100A10 (<i>S100a10</i> , p11) Sphingosine kinase 1 (<i>Sphk1</i>) CD109 (<i>Cd109</i>) Cyclooxygenase-2 (<i>Ptgs2</i> , COX2) Epithelial membrane protein 1 (<i>Emp1</i>) Solute carrier family 10 member 6 (<i>Slc10a6</i>) Transmembrane 4 L6 family member 1 (<i>Tm4sf1</i>) B3GNT5 (<i>B3gnt5</i>) CD14 (<i>Cd14</i>) STAT3 (<i>Stat3</i>) | B cell activation Transglutaminase enzyme Activate the classical pathway of complement and facilitate pathogen recognition Transport of neurotransmitters (serotonin), receptor for tissue-type plasminogen activator Regulates proliferation and survival Involved in degradation of TGFβ receptor 1 Promote inflammation Cell migration and proliferation Sodium-dependent transporter Role in cell development, activation, growth and motility Enzyme Co-receptor for the detection of bacterial lipopolysaccharide Essential for the differentiation of the TH17 Helper T cells |

Aldh1l1: Aldehyde dehydrogenase 1 family member L1; Amigo: Amphoterin-induced protein 2; AQP4: Aquaporin 4; B3GNT5: Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase; EEAT: Excitatory amino-acid transporter; GFAP: Glial fibrillary acidic protein; GGTA1: Alpha-1,3-galactosyltransferase; GPP2: Glycerol-1-phosphate phosphohydrolase 2; FKBP5: FK506 binding protein 5; PSMB8: Proteasome subunit beta type-8 (20S proteasome subunit beta-5i); STAT3: Signal transducer and activator of transcription 3






Figure 3







Figure 4

[Click here to access/download;Figure;Figure_4.tiff](#)







[Click here to access/download](#)

Supplementary Material

EJNMMI_2019_MINC_Proceedings_Supplement_MINC_
Faculty.docx

